How the FDA Regulates Artificial Intelligence in Healthcare — and What It Means for Patients in 2026

Why FDA oversight of AI matters to patients

Artificial intelligence is now used in U.S. healthcare for tasks like reading X-rays, detecting heart rhythm problems, flagging high-risk patients, and helping doctors draft notes. Some of these tools are regulated by the U.S. Food and Drug Administration (FDA) as medical devices. Others — including many general-purpose chatbots — are not.

For patients and families, the practical takeaway is simple: “FDA-cleared” does not mean perfect, and not every AI tool used in healthcare is FDA-regulated. Understanding the difference can help you ask better questions and make informed decisions.

What counts as AI-enabled Software as a Medical Device (SaMD)?

The FDA regulates certain software as a medical device, often called “Software as a Medical Device” (SaMD). According to the FDA’s Digital Health Center of Excellence, software qualifies as a medical device if it is intended to diagnose, treat, prevent, or mitigate disease.

Examples of AI tools that may fall under FDA oversight include:

Software that analyzes a CT scan to detect a stroke.
An algorithm that identifies diabetic retinopathy from retinal images.
A program that interprets ECG data to detect abnormal heart rhythms.

In these cases, the software’s output can directly influence medical decisions.

By contrast, many tools are not regulated as medical devices. These may include:

General health chatbots that provide educational information.
Appointment scheduling or billing automation tools.
AI systems that draft clinical notes but do not provide diagnostic recommendations.

If a tool does not claim to diagnose or guide treatment, it may not fall under FDA medical device rules — even if it uses advanced AI.

FDA clearance vs. approval: What’s the difference?

When a company says its AI tool is “FDA-cleared” or “FDA-approved,” those terms are not interchangeable.

510(k) clearance

Many AI-enabled devices go through what is called the 510(k) pathway. In plain language, this means the company must show the new device is “substantially equivalent” to a device already legally on the market. The evidence usually includes performance testing and clinical validation data.

This is called “clearance,” not approval.

De Novo classification

If no similar device exists, a company may go through the De Novo pathway. This is used for novel, moderate-risk devices. The FDA reviews evidence to determine whether the tool is reasonably safe and effective for its intended use.

Premarket Approval (PMA)

Higher-risk devices may require Premarket Approval (PMA), the FDA’s most stringent review process. PMA typically requires stronger clinical evidence, sometimes including prospective studies.

According to FDA guidance on AI/ML-enabled medical devices, the level of evidence depends on the risk of the device and how it is used.

Important: Clearance or approval means the tool met regulatory standards for a specific intended use. It does not mean the tool is error-free, superior to clinicians, or appropriate for every patient.

What “clinical validation” really means

Before an AI medical device is cleared or approved, it must be validated — meaning tested to see how well it performs.

Peer-reviewed discussions in journals such as the New England Journal of Medicine and JAMA emphasize that validation should answer key questions:

How accurate is the tool? (Often measured by sensitivity and specificity.)
Was it tested on patients similar to those who will use it in real-world practice?
Was the evaluation retrospective (using existing data) or prospective (tested in real time in clinical care)?

Retrospective studies use past data. They are common and useful but may not reflect real-world clinical complexity. Prospective studies, which test the tool in live clinical settings, often provide stronger evidence but are more difficult and expensive to conduct.

Experts have also raised concerns about bias — if the training data underrepresent certain racial, ethnic, age, or language groups, the tool may not perform equally well for everyone.

How the FDA approaches adaptive or “learning” AI

One of the biggest challenges is that some AI systems can change over time as they learn from new data.

The FDA has outlined a “total product lifecycle” approach for AI/ML-enabled medical devices. This includes:

Expectations for Good Machine Learning Practice.
Predetermined change control plans — meaning manufacturers must describe in advance what kinds of updates or modifications they plan to make.
Ongoing monitoring after the device is on the market.

This framework is still evolving. The FDA has acknowledged that continuously learning systems present regulatory challenges, especially when performance may shift as patient populations or clinical practices change.

What happens after clearance?

FDA oversight does not end when a device enters the market.

Manufacturers must follow post-market requirements, which can include:

Reporting certain adverse events.
Monitoring real-world performance.
Updating labeling or issuing safety communications if problems are identified.
Recalls when necessary.

The FDA’s Digital Health Center of Excellence oversees much of this work for digital and AI-enabled products.

In other words, clearance is not a one-time stamp. It is part of an ongoing regulatory process.

Known limitations: Bias, drift, and overreliance

Even when FDA-cleared, AI systems have known limitations.

Bias

If the data used to train a system do not reflect the diversity of real patients, performance can vary across groups.

Dataset shift and performance drift

When clinical practices change or new populations use the tool, accuracy may decline. This is sometimes called performance drift.

Overreliance

Research discussed in major medical journals warns that clinicians may sometimes over-trust algorithmic outputs, especially when presented with high confidence scores. Human oversight remains essential.

The World Health Organization’s guidance on AI in health also emphasizes transparency, accountability, and careful governance to reduce risks.

What this means for patients

If AI is being used in your care, you have the right to ask questions. You do not need to understand regulatory filings to have a meaningful conversation.

Consider asking:

Is this tool FDA-cleared or approved for this specific use?
Was it validated in patients like me?
Who reviews the results before decisions are made?
What happens if the tool is wrong?
Does this affect my insurance coverage or costs?

Remember, AI tools that assist with documentation or scheduling are different from those that influence diagnosis or treatment decisions. The level of oversight may differ accordingly.

The bottom line in 2026

Some AI tools in U.S. healthcare are regulated by the FDA as medical devices. Others are not.

FDA clearance means a tool met defined safety and effectiveness standards for a specific intended use — not that it is perfect or universally safe.

Because AI systems can change over time, ongoing monitoring matters. Bias, performance drift, and overreliance remain real concerns.

Most importantly, human clinicians remain responsible for final medical decisions. AI may assist, flag, or analyze — but it does not replace professional judgment.

For patients and families, the goal is not to fear AI or blindly trust it. It is to stay informed, ask clear questions, and remain active participants in your own care.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.